Clinical pharmacology of acetylsalicylic acid as an anti-thrombotic agent

被引：0

作者：

Rafalsky, V. V. ^{[1
]}

Krikova, A. V. ^{[1
]}

Baglikov, A. N. ^{[1
]}

机构：

[1] Smolensk State Med Acad, Smolensk, Russia

来源：

CARDIOVASCULAR THERAPY AND PREVENTION | 2009年 / 8卷 / 07期

关键词：

Acetylsalicylic acid; prevention; cardiovascular disease; LOW-DOSE ASPIRIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTRIC-MUCOSAL DAMAGE; CORONARY-HEART-DISEASE; HELICOBACTER-PYLORI; RISK; PREVENTION; PHARMACOKINETICS; CYCLOOXYGENASE; COMPLICATIONS;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Currently, acetylsalicylic acid (ASA) is one of the main medications in cardiovascular prevention. Preventive ASA therapy has some specific pharmacokinetic and pharmacodynamic features, also depending on the medication form. The maximal ASA effectiveness is observed for low doses of 75-150 mg/d. The main adverse effect (AE) of preventive ASA therapy is gastro-toxicity which could be reduced by prescribing low ASA doses, being aware of other risk factors, and choosing optimal medication forms. Gastro-intestinal (GI) AE could also be prevented and treated with proton pump inhibitors, while antacids do not reduce ASA gastro-toxicity. Comparing to standard ASA forms, intestine-soluble forms are characterised by lower risk of gastric ulcers and erosions, heartburn, and pain symptoms.

引用

页码：102 / 107

页数：6

共 37 条

[1] Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs:: A case-control study [J].